Introduction {#s0001}
============

*Interleukin 10* (*IL10*) is an immune regulatory cytokine with non-redundant roles in anti-inflammatory responses,[@cit0001] B-cell proliferation,[@cit0002] and differentiation of T and B cell subsets.[@cit0003] In addition, it has important roles in the polarization of specific macrophage subsets, both in infectious conditions and cancer.[@cit0005]

Inter-individual differences in *IL10* production have a hereditary component estimated in 75%,[@cit0007] mainly due to the effect of promoter polymorphisms,[@cit0008] such as the three proximal single nucleotide polymorphisms (SNPs), at positions −1082(A/G), −819(C/T), and −592(C/A) base pairs from the transcription start site.[@cit0008] Furthermore, genetic modifiers upstream of the transcription initiation site have been described.[@cit0010] However, the model of the genetic control of *IL10* expression has not reached a consensus yet, and results may vary according to cell type and *in vitro* activation stimuli.[@cit0012]

Due to its functions in B cell biology and its ability to induce a suppressor microenvironment, IL10 is an ongoing target in B-cell lymphoma research.[@cit0015] Classical Hodgkin lymphoma (cHL) is a B-cell neoplasm characterized by the presence of scarce tumor (Hodgkin-Reed-Sternberg, H-RS) cells surrounded by inflammatory non-neoplastic cells, collectively known as tumor microenvironment (TME), which pathogenic role is increasingly recognized.[@cit0017] In cHL adult patients, high IL10 serum levels are mainly associated with tumor burden (advanced disease stage, elevated LDH and β2-microglobulin levels) and unfavorable host-tumor factors (presence of B symptoms, anemia, low serum albumin levels), as well as a short survival.[@cit0019] Associations of *IL10* promoter polymorphisms with clinical outcome have been described in some studies with adult cHL patients,[@cit0025] while in others this association has not been found.[@cit0027] Moreover, an analysis of the relationship between *IL10* genotype and its influence in local mRNA expression and cellular profiles in the TME of cHL is lacking. The main goal of this study was to find clinical and biological correlates of *IL10* promoter proximal polymorphisms in children and adolescent with cHL. Given the important functions of this cytokine in the immune response, and the recognized role of TME in cHL therapeutic response, we hypothesize that clinical outcome imparted by *IL10* genetic variants may be mediated by effects on the tumor microenvironment composition or modulation.

Results {#s0002}
=======

Clinical and epidemiological characteristics of patients {#s0002-0001}
--------------------------------------------------------

The clinical and histological characteristics of cHL patients have been described previously.[@cit0029] Median age at diagnosis was 14 years (3--18), and sex ratio (male:female) 1.8:1. Most patients presented with stages I/II and low-risk disease (62.1% and 52.6%, respectively), mediastinal mass was observed in 65.6% and extranodal disease in 11.6% of cases. Nodular sclerosis (NS) was the most frequently observed histological subtype (69%), followed by mixed cellularity (23%). Epstein-Barr virus (EBV) was detected in 44.8% of cases (Table S1).

IL10 polymorphisms {#s0002-0002}
------------------

In total, 98 patients were successfully genotyped for *IL10* promoter rs1800896 (−1082A\>G) and 97 for the rs1800872 (−592C\>A) SNPs. Both SNPs were in Hardy-Weinberg equilibrium (−1082 *P =* 0.53 and −592 *P* = 0.08, Goodness of fit χ^2^ test). Genotypic frequencies are described in [Table 1](#t0001){ref-type="table"}. In view of the complete linkage of −819C/T and −592C/A SNPs,[@cit0030] the proximal haplotypes including the three positions (−1082A/G, −819C/T, and −592C/A) GCC, ACC and ATA were reconstructed in 96 patients. The frequency of haplotypes in cHL patients was 63.5% (61/96) for GCC; 46.9% (45/96) for ACC and 50% (48/96) for ATA. Table 1.Progression-free survival (PFS) analysis according to genotypes and haplotypes in the *IL10* promoter in children and adolescent with classical Hodgkin lymphoma diagnosis.   CI (95%) of univar.  CI (95%) of multivar. VariableNumber of EventsHR (Expβ) univar.LowerUpperUnivar. *P*-valueHR (Expβ) multivar.LowerUpperMultivar. *P*-value−1082*IL10*          GG0/16   *P* = 0.065[^§^](#t1fn0001){ref-type="fn"}     AG10/390.4950.2390.939*P* = 0.0310.3220.0950.805*P* = 0.013 AA10/33         GG0/16   *P* = 0.024[^§^](#t1fn0001){ref-type="fn"}     AG+AA20/720.0950.0010.691*P* = 0.0130.0540.0000.511*P* = 0.005−592*IL10*          AA5/10   *P* = 0.009[^§^](#t1fn0001){ref-type="fn"}     AC8/312.3501.2784.291*P* = 0.0072.3621.1574.860*P* = 0.019 CC6/46         CC6/46   *P* = 0.032[^§^](#t1fn0001){ref-type="fn"}     AC+AA13/410.3780.1380.932*P* = 0.0340.3280.1090.909*P* = 0.032Haplotypes          ACC9/43   *P* = 0.721[^§^](#t1fn0001){ref-type="fn"}     ATA+ GCC10/430.8530.3472.068*P* = 0.7231.5050.5214.700*P* = 0.454 ATA13/41   *P* = 0.035[^§^](#t1fn0001){ref-type="fn"}     GCC+ ACC6/452.6011.0557.119*P* = 0.0382.9041.0438.759*P* = 0.041 GCC10/55   *P* = 0.204[^§^](#t1fn0001){ref-type="fn"}     ACC+ATA9/310.5600.2311.375*P* = 0.2000.4050.1021.361*P* = 0.454[^2]

IL10 gene expression {#s0002-0003}
--------------------

Levels of *IL10* mRNA in cHL lymph nodes \[mean 2^−^*^ΔCq^* ± −2.515 ± 1.531 SD\] were higher than the observed in reactive follicular hyperplasia (RFH) lymph nodes (mean 2^−^*^ΔCq^*: −3.757 ± 1.235 SD) (*P =* 0.001; Student\'s t test) ([Fig. 1A](#f0001){ref-type="fig"}). Figure 1.*IL10* gene expression. (A) *IL10* relative expression in classical Hodgkin lymphoma (cHL, n = 83) and reactive follicular hyperplasia (RFH, n = 20); (B) *IL10* relative expression in classical Hodgkin lymphoma lymph nodes according to *IL10* −1082A\>G genotypes (AA, n = 32; AG, n = 38; GG, n = 12); (C) *IL10* relative expression in classical Hodgkin lymphoma lymph nodes according to *IL10* −592C\>A genotypes (CC, n = 44; AC, n = 28; AA, n = 10); (D) *IL10* relative expression in classical Hodgkin lymphoma lymph nodes according to *IL10* haplotype (GCC/GCC, n = 12; ACC/ACC, n = 8; ATA/ATA, n = 11). *P \<* 0.05 significant statistical association (Student\'s t-test).

In the cHL group, −1082GG genotype was associated with lower *IL10* mRNA expression (mean 2^−^*^ΔCq^* −3.517 ± 2.009 SD) than AG+AA genotypes (2^−^*^ΔCq^*: −2.346 ± 1.392) (*P* = 0.014; Student\'s t-test) ([Fig. 1B](#f0001){ref-type="fig"}). Genotypes of the −592 SNP showed no association with *IL10* mRNA expression ([Fig. 1C](#f0001){ref-type="fig"}). In the RFH group, no significant associations between −1082 or −592 SNP genotypes and *IL10* gene expression levels could be disclosed, likely due to the small number of samples analyzed. In respect of *IL10* haplotypes, a trend to high *IL10* expression in ATA and ACC carriers was observed, while the opposite occurred with GCC/GCC cHL cases ([Fig. 1D](#f0001){ref-type="fig"}).

IL10 genetic polymorphisms and mRNA expression in respect of clinical characteristics and therapy response {#s0002-0004}
----------------------------------------------------------------------------------------------------------

Patients with high *IL10* mRNA expression (2^-*ΔCq*^ \> −2.243, median of the group) presented more frequently with B symptoms (64.3% *vs.* 35.7% in low expression patients; *P* = 0.013; χ^2^ test). No associations between *IL10* promoter polymorphisms or expression level were observed in respect of Ann-Arbor stage, age, histopathology subtypes, EBV status, extranodal commitment, and mediastinal mass.

Median follow up of the patient group was 65.5 months (72 months for censored patients). Progression-free survival (PFS) with 5 years follow-up was 78.6%. A poor PFS was associated, in univariate analysis, with leukopenia, extranodal disease, MC subtype and high numbers of Granzyme B+ lymphocytes, as described previously.[@cit0029]

Genotypes of the −592A/C SNP influenced prognosis, with worse PFS exhibited by −592AA patients (50%), when compared with AC (74.2%), and CC patients (87.0%) (*P* = 0.009, log-rank test). Patients with the −1082GG genotype showed a better PFS (100%) than AG and AA carriers (72.2%) (*P* = 0.024, log-rank test) ([Table 1](#t0001){ref-type="table"} and [Figs. 2A-D](#f0002){ref-type="fig"}). Figure 2.Kaplan-Meier curves for progression-free survival (PFS) of pediatric classical Hodgkin lymphoma according to evaluated IL10 promoter polymorphisms. (A) PFS according to *IL10* −1082A\>G genotypes; (B) PFS comparing −1082GG *vs.* AG+AA genotype carriers; (C) PFS according to *IL10* −592C\>A genotypes; (D) PFS comparing −592CC *vs.* AC+AA genotype carriers; (E) PFS of ATA haplotype carriers *vs.* others haplotypes. *P\<* 0.05 significant statistical association (log-rank test).

Patients carrying the ATA haplotype showed worse PFS (68.3%) when compared to other haplotypes (86.7%) (*P* = 0.035, log-rank test; [Fig. 2E](#f0002){ref-type="fig"}). The significance was maintained after application of Firth\'correction ([Table 1](#t0001){ref-type="table"}). Thus, genotypes and haplotypes associated with high *IL10* expression levels were shown to be associated to a shorter PFS. None of the *IL10* genetic variants were associated with overall survival (OS) (Table S2).

In multivariate analysis performed by Firth\'s penalized Cox regression, considering the clinical and microenvironment variables with described PFS impact, −10822 GG genotype (HR: 0.054, 95% CI 0.000--0.511, *P* = 0.005), the −592 CC genotype (HR: 0.328, 95% CI 0.109--0.909, *P* = 0.032) and the ATA haplotype (HR: 2.904, 95% CI 1.043--8.759; *P* = 0.041) retained prognostic impact ([Table 2](#t0002){ref-type="table"}). Table 2.Multivariate Cox regression with Firth correction, considering *IL10* genotypes/haplotypes along with other clinical and microenvironment variables influencing PFS in pediatric classical Hodgkin lymphoma. (A) Model I, −1082 GG genotype; (B) Model II, --592 CC genotype; (C) Model III, ATA haplotype.(A)     Confidence Interval (95%) VariableHR (Expβ)LowerUpper*P*-valueExtranodal sites6.6411.82021.6840.006High number of Granzyme B cells4.1791.21822.1220.021Leukopenia2.8220.8487.7560.086Mixed cellularity3.6371.24210.0760.020−10822 GG genotype0.0540.0000.5110.005[^3] (B)     Confidence Interval (95%) VariableHR (Expβ)LowerUpper*P*-valueExtranodal sites4.4511.31412.7160.019High number of Granzyme B cells6.2091.50457.2000.008Leukopenia3.3130.82310.5350.086Mixed cellularity2.8500.9787.7530.055−592 CC genotype0.3280.1090.9090.032[^4] (C)     Confidence Interval (95%) VariableHR (Expβ)LowerUpper*P*-valueExtranodal sites4.2651.26012.1740.022High number of Granzyme B cells6.8531.62263.8880.006Leukopenia3.2650.81110.4020.089Mixed cellularity2.9261.0077.9230.049ATA haplotype2.9041.0438.7590.041[^5]

Association of IL10 genetic variants with the tumor microenvironment cell composition {#s0002-0005}
-------------------------------------------------------------------------------------

In view that genotypes and haplotypes determining high levels of *IL10* mRNA in lymph nodes were associated to an unfavorable prognosis, we next asked if *IL10* genetic background may dictate some aspects of the TME composition in cHL. In this work, given the roles of MAF transcription factor in the control of *IL10* expression,[@cit0032] expression of MAF by the TME cells was used as a surrogate for cell commitment to express *IL10*.

Distribution of lymphocyte and macrophage sub-populations in the TME in relation to age group, histology, EBV-status and their prognostic impact have been previously reported.[@cit0029] MAF expression by H-RS cells was observed in only two cases and in few cells. Patients with −1082GG (low *IL10* expression) and −592CC genotypes exhibited low numbers of MAF+ inflammatory cells (median: 20 *vs.* 78 cells/mm^2^, and median: 49 *vs.* 108 cells/mm^2^; *P =* 0.012 and *P =* 0.003, respectively; Mann-Whitney test) ([Fig. 3A](#f0003){ref-type="fig"}, [B](#f0003){ref-type="fig"}). Moreover, −1082GG patients exhibited low percentages of CD68+MAF+ macrophages (15.04% *vs.* 47.26% for the other genotypes, *P* = 0.017; Mann-Whitney test) ([Fig. 3C](#f0003){ref-type="fig"}, Table S3). Conversely, ATA haplotype (high level *IL10* expression) was associated with high numbers of MAF+ inflammatory cells (median 108 *vs.* 49 cells/mm^2^, *P =* 0.005; Mann-Whitney test) ([Fig. 3D](#f0003){ref-type="fig"}, Table S3). Figure 3.Number of cells expressing the MAF transcription factor according to *IL10* genotypes and haplotypes. (A) Numbers of MAF+ cells according to −1082 genotypes (AA, n = 26; AG, n = 36; GG, n = 13); (B) Numbers of MAF+ cells according to −592C\>A genotypes (CC, n = 42; AC, n = 25; AA, n = 7); (C) Percentages of CD68+MAF+ macrophages according to −1082A\>G genotypes (AA, n = 24; AG, n = 32; GG, n = 13); (D) Numbers of MAF+ cells in ATA haplotype (n = 33) *vs.* carriers of other haplotypes (n = 40). *P \<* 0.05 significant statistical association (Mann-Whitney test).

Since EBV may modulate the TME, with EBV-associated cases being characterized by significantly higher numbers of cytotoxic/Th1 lymphocytes and macrophages than EBV- group[@cit0029] we decided to investigate potential interactions between EBV and the studied SNPs in the TME composition. For this, we have defined a ratio of FOXP3+ over CD8+ and TBET+ cells; and MAF+ over CD8+ and TBET+ cells as indicating a predominantly Th2/regulatory TME, and then analyzed these cell population balances in cases stratified by *IL10* genotypes and EBV status.

Analyses were conducted by linear logistic regression using log10-transformed raw cell ratios as dependent variable. The MAF+/TBET+ ratio showed to be inversely dependent on both, the EBV presence and low *IL10* expression-associated −1082GG genotype (*P* = 0.020), or −592CC genotype (*P* = 0.031), or GCC haplotype (*P* = 0.045) (Table S4), indicating a significant effect of both EBV and *IL10* genotypes/haplotypes in the TME modulation ([Fig. 4](#f0004){ref-type="fig"}). Figure 4.Main effect plots of EBV status and −592 genotypes on the tumor microenvironment polarization, measured by the distribution of the MAF+/TBET+ cell ratios. Variables are normalized to a 0--1 range. The graphic was constructed with the statistical R environment.

Discussion {#s0003}
==========

A large number of studies have demonstrated that H-RS cells may be able to modulate their microenvironment, e.g., by the production of cytokines and chemokines, contributing to an immunosuppressive TME and survival of these neoplastic cells.[@cit0018] In this context, *IL10* functional genetic variants that are being strongly considered in the search for prognostic markers in cHL, may also be factors of the disease histopathogenesis.

Our first aim was to validate the impact of *IL10* polymorphisms on disease prognosis in our series of pediatric cHL. In our pediatric cohort, the −1082AA+AG genotypes and ATA haplotype were associated with unfavourable prognosis, in agreement with previous results in adult cHL patients, in which an unfavourable outcome was associated with *IL10* ATA/ATA haplotypes[@cit0026] and the presence of the −592AA genotype.[@cit0025] Considering ours as an independent validation cohort, our results give support to the clinical importance of *IL10* genetic variants in the full spectrum of cHL, by demonstrating an association also in the pediatric population.

We next intended to find phenotypic correlates that may help to explain ours and other\'s clinical results. Our methodological approach to draw genotype-phenotype associations was based on the quantification of mRNA levels and cells in tumor tissues, the higher levels of *IL10* expression in cHL lymph nodes *vs.* RFH lymph nodes pointed to the immunosupressor phenotype as a pathogenic factor in the former condition.

In studies based on IL10 systemic levels, it is still a matter of debate whether IL10 levels reflect its direct participation in cHL pathophysiology, or merely reflect the effect of tumor burden on a drained immune system. Our findings of high levels of tumor *IL10* expression associated with B symptoms, as well as the association of high-expression *IL10* promoter polymorphisms with an unfavorable therapeutic response reinforce the idea of a direct role of IL10 in cHL pathogenesis and are in line with several studies reporting high IL10 serum levels associated to unfavorable disease characteristics, therapy response and short survival in cHL patients.[@cit0019]

We next addressed the phenotypic correlations of *IL10* proximal promoter polymorphisms. In our system, which relies not in experimental cell activation, but in the state of activation and number of infiltrating and H-RS cells in tumor lymph nodes, we found that −1082A/G genotypes have a leading role in modulating *IL10* expression, with ATA-associated genotypes and haplotypes contributing to *IL10* high expression levels. The association of −1082GG genotype with low expression was somewhat surprising, since previous studies have found this genotype associated with IL10 high expression levels.[@cit0009] However, *in vitro* assays have shown that the −1082A allele was associated with the highest IL10 production when the position was isolated against a constant haplotype background.[@cit0037] The −1082A allele was also correlated with high IL10 expression in whole blood from rheumatoid arthritis patients stimulated in vitro with lipopolysaccharide;[@cit0038] in peripheral blood mononuclear cells stimulated with ConA;[@cit0039] as well as in plasma of healthy individuals.[@cit0040]

Discrepancy with the studies that found −1082GG genotypes associated with high expression levels[@cit0009] may be a consequence of different activation conditions and of the diversity in cell compositions of the experimental models. In fact, it has been described, but not yet completely explored in complex systems, that *IL10* promoter occupancy may vary according to cell lineages (i.e. lymphocytes, monocytes and macrophages)[@cit0003] where epigenetic mechanisms might be modulated by the diverse microenvironment stimuli.

In agreement with that concept, we observed scarce numbers of MAF+ neoplastic cells, while MAF expression by inflammatory cells was variable, pointing to diverse IL10 activating pathways in the different cell lineages.[@cit0003]

*IL10* genetic variants determining high *IL10* mRNA levels were furthermore associated with high numbers of inflammatory cells expressing MAF. Thus, assuming the premise that MAF is an important *IL10* transcription factor in immune cells,[@cit0032] the model of *IL10* mRNA genetic control was replicated at the cellular level, at least in the TME. Since the main associations were observed between *IL10* polymorphisms and MAF expression by inflammatory cells, the action in *cis* of *IL10* polymorphisms on the MAF ligation domain in *IL10* promoter is a probable explanation. The MAF recognition element (MARE) localizes to −196/−184 in the *IL10* promoter, and has been demonstrated functional by both *in vitro* (EMSA) and *in vivo* (ChIP assay) experiments.[@cit0032] It is likely therefore that one of the effects of the proximal promoter polymorphisms is to modulate the binding of MAF to its recognition element in *IL10* promoter, thereby leading to a more elevated *IL10* expression rate. High expression levels of *IL10* in serum and TME might then mediate a positive loop of enrichment in monocytes with an immunosuppressive phenotype (and consequently M2-like macrophages) as described in B cell non-Hodgkin lymphoma.[@cit0042]

Additionally, we were able to disclose an inverse correlation of *IL10* expression levels with the number of TBET+ lymphocytes (Th1) and a subset of dendritic cells. This may reflect the inverse numerical relationships in Th1-oriented and Th2/Treg-oriented microenvironments[@cit0043] and allows hypotheses about a yet unproven role of the cytokine in the *in situ* differentiation and activation of intratumoral lymphocytes and dendritic cells.

Macrophages are plastic cells with potentiality to both pro-inflammatory and regulatory functions.[@cit0006] The role of tumor-associated macrophages in the prognosis of cHL is still controversial, with some studies showing association of high counts/density of TAM with poor survival in adult cHL,[@cit0045] while some others failed to disclose such association.[@cit0048] This discrepancy may be due to differences in immunohistochemical biomarkers and scoring systems.[@cit0050] However, it is possible that part of this lack of reproducibility results from TAMs heterogeneity. In fact, in pediatric cHL, we have recently shown that M2-like macrophages, and not M1 macrophages, were associated with a poor outcome.[@cit0031] Moreover, the pathogenic role of immunosuppressive macrophages in cHL is being highlighted in preclinical studies targeting TAMs with chimeric antigen receptor T cell (CART) therapy.[@cit0051]

In this work, we extended our previous results, by showing that percentages of intratumoral MAF-expressing, M2-like-polarized macrophages were correlated with *IL10* genotypes, suggesting a role of the host genetic background in the susceptibility to polarize intratumoral macrophages to a suppressor phenotype, indirectly participating in the microenvironment shaping.

In this study, we were not able to disclose any consistent association of EBV with *IL10* polymorphisms or MAF expression. Previous studies have shown an increased IL10 production in EBV+ H-RS cells[@cit0052] and a role of *IL10* expression by H-RS cells in the evasion of viral-directed cytotoxicity,[@cit0054] suggesting that IL10 might mediate local effects of autocrine stimuli and/or immune escape in H-RS cells. In this study, *IL10* expression level was measured by mRNA analysis of the whole lymph node, thus detected levels represent the contribution of both, H-RS and infiltrating cells. In that regard, since EBV in pediatric cHL is associated with a cytotoxic/Th1 oriented TME,[@cit0029] not being able to detect a difference regarding *IL10* expression level in EBV+ and EBV- cases is not surprising. Further studies to better discriminate the patterns of *IL10* expression at the cellular and molecular level by tumor *vs.* infiltrating cells in respect of EBV status would help to clarify this issue, including the interaction between EBV- and IL10-mediated TME modulations.

To our knowledge, this is a first study to show an association between *IL10* genotype and phenotype in patients with cHL at the molecular, cellular, and clinical levels. While we are aware of the limitations imposed by the number of patients, we reinforce that the main goal of this study was drawing biological and immunological correlates from meaningful clinical factors, to help highlighting pathogenic mechanisms in a complex disease such as cHL. On the whole, our results contribute to fill a gap in the knowledge of the relationship between *IL10* genotype and phenotype in cancer, and advance the concept of genetic control of microenvironment composition as the basis of susceptibility and therapeutic response.

Materials and methods {#s0004}
=====================

Patients and samples {#s0004-0001}
--------------------

Ninety-eight HIV-negative children and adolescents (up to 18 year old) diagnosed with cHL at the Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil, between 1999 and 2006, were included in this study. All included patients in this study were evaluated by a minimal follow-up of 60 months.

Diagnosis of cHL was based on morphologic criteria[@cit0055] and immunohistochemical (IHC) characterization.[@cit0056] Latent EBV infection has been investigated previously in all cHL cases by EBER-ISH hybridization.[@cit0056] All patients were treated according to adriamycin-based standard pediatric protocols, as described.[@cit0029] Additionally, 20 patients with HIV-negative RFH diagnosis were included as controls of *IL10* expression (median age: 36 year, 4 -- 83). This study was approved by the INCA Ethics Committee (Number 37/05 and CAAE 56999916.5.0000.5274) and all patients were included after signed informed consent.

Nucleic acids extraction {#s0004-0002}
------------------------

DNA was extracted using QIAamp® DNA FFPE Tissue (Qiagen®, catalog number 56404) from three to five microtomized sections (3 μm) of formalin-fixed, paraffin-embedded (FFPE) lymph nodes. Total RNA was obtained with the Master Pure™ kit (Epicentre®, catalog number MCR85102), as described.[@cit0057] All working conditions were RNase-free. The quantity and purity of nucleic acids was evaluated using a Nanodrop®, ND-1000 Spectrophotometer (Wilmington, Delaware USA) at λ260/280/230 ratios, and additionally, a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) for RNA quality.

IL10 genotyping {#s0004-0003}
---------------

The single nucleotide polymorphisms (SNPs) rs1800896 (−1082A\>G) and rs1800872 (−592C\>A) (catalog number: C_1747360_10 and C_1747363_10, respectively) were genotyped using TaqMan® assays in a Viia7 platform (Applied Biosystems, Life Technologies™, Carlsbad, CA), using 3 ng/µL of DNA in 15 µL final volume. Thermal profile was 50°C for 2 min, 95°C for 10 min and 50 cycles at 92°C for 15 s and at 60°C for 90 s. A post-read step of 1 min at 60°C allowed allelic discrimination. Controls with known *IL10* genotypes (2 samples for each homozygote and heterozygote genotype) as well as 2 negative template controls were included in each run; 10% of samples were randomly selected to be re-genotyped in the next run.

IL10 gene expression {#s0004-0004}
--------------------

cDNA was prepared from 500 ng of total RNA in 20 µL final volume, using High-Capacity cDNA Archive kit (Applied Biosystems, catalog number 4368814). A pre-amplification step was performed, using the TaqMan® PreAmp Master Mix (Applied Biosystems). *IL10* expression was quantified using a TaqMan® assays (Hs00961622_m1, Applied Biosystems) in 15 µL final volume with standard 50-cycles thermal cycling. *GUSB* (Hs99999908_m1) and *HMBS* (Hs00609297_m1) were used as reference genes. Each measurement was performed in duplicate and quantified by *Cq-*value with fixed thresholds. Samples were considered amplifiable with *Cq*-values \<35 cycles, and only duplicates with SD ≤0.15 cycles were accepted. The quantification values were expressed as log2 (2-ΔCq) after normalization with the mean level expression of the reference genes.[@cit0058]

Immunohistochemical characterization of tumor microenvironment {#s0004-0005}
--------------------------------------------------------------

A tissue microarray (TMA) block was built as described previously.[@cit0029] The immune cells from the TME were identified by single or double immunohistochemistry, as described previously,[@cit0029] with primary antibodies described in Table S5. Briefly, immunodetection was performed using ZytoChem Plus HRP polymer kit (Zytomed Systems, catalog number: POLHRP-100), employing diaminobenzidine (DAB) chromogen as substrate for single IHC techniques, and with AP Polymer System (Zytomed Systems, catalog number: POLAP-100), employing Blue Alkaline Phosphatase (Vector Laboratories, catalog number: SK-5300) as substrate for double detection IHC. IL10 producing cells were identified by the expression of MAF, an essential transcription factor for *IL10* gene expression in T lymphocytes and macrophages.[@cit0003] The computer assisted cell quantification was performed with the image analysis software HISTO (Biomas, Erlangen, Germany), as described previously.[@cit0029]

The identification of all MAF+ cells were performed by single IHC, while the specific identification of MAF+ macrophages was performed by double IHC.[@cit0059] MAF+ inflammatory cells and MAF+ macrophages were expressed as absolute number/mm^2^. Additionally, MAF+ macrophages were expressed as a percent value of CD68+ or CD163+ macrophages, as follow (number of MAF-expressing CD68+ or CD163+ macrophages/ total number of CD68+ or CD163+ macrophages) x 100.

Statistical analyses {#s0004-0006}
--------------------

Student\'s t test and one-way ANOVA were used for comparing gene expression levels of two or multiple groups. Mann-Whitney\'s test was used to analyze associations between dichotomous and continuous non normal variables such as cell numbers in the TME, while Spearman\'s test was used for correlating continuous variables. Pearson\'s chi-square and Fisher\'s exact test were used for testing association in dichotomous variables. *P*-values \<0.05 were considered as significant in 2-tailed tests. PFS was the time in months between diagnoses to relapse associated to cHL, initiation of other unplanned treatment or last follow-up, and OS the interval in months between diagnosis to death by any cause or last follow-up. Kaplan-Meier method and the log-rank test were used for estimating and comparing the distribution of survival probabilities. Additionally, univariate and multivariate penalized Firth logistic regressions were performed to reduce possible bias estimation effects due to small sample number. The proportionality assumptions for multivariate analysis were analyzed by time dependent covariance (*P*\> 0.05 assumption satisfied). Higher order interactions between SNP and clinical parameters were not investigated. Statistical Package for the Social Sciences (SPSS) 20.0 software and CRAN R-project were used for statistical analyses.
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